Liquid Biopsy - Microfluidic concepts for the isolation of biomarkers

• Expand your portfolio (e.g. analysis of microorganisms, prenatal diagnostics) with our innovative microfluidic diagnostic platform and open up new target markets in the long term.
  
• Reduce workload and simplify the operation of your solution thanks to flexible and automated integration of sample preparation inside or outside your solution.   
  
• Strengthen your innovative power and bundle resources where they can unleash their efficiency: Through long-term joint further development of projects, we support you with our expertise from the project idea onwards, including risk analysis.
  

Are first clinical studies already underway?

Together with clinical partners, we have already been able to examine several tumor samples and conduct the first promising follow-up examinations of isolated tumor cells. We have also been able to automatically isolate and analyze exosomes from urine of prostate cancer patients. We are very interested in a large-scale clinical study - please contact us!

How robust is the automated process compared to the manual method?

With our automated process, we have achieved a robust protocol with a comparable isolation efficiency. *

• The CTCelect liquid biopsy platform was developed to realize fully automated enrichment and single cell dispensing of CTCs from whole blood without pre-processing. We optimized each process step with two different carcinoma cell lines with a standard deviation of approximately 10 %, demonstrating up to 87 % enrichment (n = 10) with EpCAM-coupled immunomagnetic beads, 73 % optical detection and dispensing efficiency (n = 5). 40 to 56.7 % of cells were recovered after complete isolation from 7.5 ml of untreated whole blood (n = 6). *    
  
• Automated cfDNA enrichment from human plasma in a duplicated standard series was reproducible at 99.9 % (R2=0.9996) [unpublished data].   
  
• The yield of extracellular vesicles (uEVs) isolated automatically from urine with our platforms for e.g. prostate cancer monitoring was approx. 2/3 higher than the yield of manually isolated uEVs. *
   

How can we work together and can you customize your process and biomarker targets?

In joint research and development work, we are happy to help you integrate target-specific immunoassays into our process automation. Our platform technology is very flexible.

* corresponding publications can be found on the right